All Stories

  1. Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients
  2. Minimum Core Data Elements for Transcatheter Mitral Therapies
  3. Ventricular Remodeling and Outcomes After Mitral Transcatheter Edge-to-Edge Repair in Heart Failure
  4. Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials
  5. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials
  6. Severity of and Recovery From Anemia After Transcatheter Aortic Valve Replacement: An Analysis of the PARTNER Trials and Registries
  7. Minimally Invasive Versus Full Sternotomy for Isolated Aortic Valve Replacement in Low-Risk Patients
  8. Association Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes
  9. Impact of Right Ventricle-Pulmonary Artery Coupling on Clinical Outcomes in the PARTNER 3 Trial
  10. Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement
  11. Minimum Core Data Elements for Evaluation of TAVR
  12. Minimum Core Data Elements for Evaluation of TAVR
  13. Characteristics and clinical outcomes in patients with prior chest radiation undergoing TAVR: Observations from PARTNER‐2
  14. Impact of Frailty and Prefrailty on Outcomes of Transcatheter or Surgical Aortic Valve Replacement
  15. Paravalvular regurgitation after transcatheter aortic valve replacement in intermediate-risk patients: a pooled PARTNER 2 study
  16. Time-of-Day and Clinical Outcomes After Surgical or Transcatheter Aortic Valve Replacement: Insights From the PARTNER Trials
  17. Right Ventricular–Pulmonary Arterial Coupling in Patients With HF Secondary MR
  18. Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial
  19. Impact of Flow on Prosthesis-Patient Mismatch Following Transcatheter and Surgical Aortic Valve Replacement
  20. Relation between Modified Body Mass Index and Adverse Outcomes after Aortic Valve Implantation
  21. Impact of Predilation During Transcatheter Aortic Valve Replacement: Insights From the PARTNER 3 Trial
  22. Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement
  23. Prosthesis-Patient Mismatch After Aortic Valve Replacement in the PARTNER 2 Trial and Registry
  24. Atrial Fibrillation and Outcomes After Transcatheter or Surgical Aortic Valve Replacement (from the PARTNER 3 Trial)
  25. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research
  26. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research
  27. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk
  28. A neural system dynamics modeling platform and its applications in randomized controlled trial data analysis
  29. Diastolic Function and Clinical Outcomes After Transcatheter Aortic Valve Replacement
  30. Association of Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement With Subsequent Clinical Outcomes
  31. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial
  32. Impact of Transcatheter Aortic Valve Replacement on Severity of Chronic Kidney Disease
  33. Outcome of Flow-Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement
  34. Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement
  35. Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR
  36. Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries
  37. Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients
  38. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement
  39. Mitral regurgitation in patients undergoing transcatheter aortic valve implantation for degenerated surgical aortic bioprosthesis: Insights from PARTNER 2 Valve‐in‐Valve Registry
  40. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
  41. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry
  42. Prosthetic Valve Endocarditis After TAVR and SAVR
  43. Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
  44. Impact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries
  45. Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement
  46. Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation
  47. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement
  48. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses
  49. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
  50. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial
  51. Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement
  52. Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis
  53. How Cox models react to a study-specific confounder in a patient-level pooled dataset: random effects better cope with an imbalanced covariate across trials unless baseline hazards differ
  54. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial
  55. Outcomes of Patients with Significant Obesity Undergoing TAVR or SAVR in the Randomized PARTNER 2A Trial
  56. Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial
  57. Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement
  58. The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA
  59. Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER-2A
  60. Sex-Specific Outcomes of Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve
  61. Transapical Transcatheter Aortic Valve Replacement Is Associated With Increased Cardiac Mortality in Patients With Left Ventricular Dysfunction
  62. Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve
  63. Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial
  64. CT-Defined Prosthesis–Patient Mismatch Downgrades Frequency and Severity, and Demonstrates No Association With Adverse Outcomes After Transcatheter Aortic Valve Replacement
  65. Staging classification of aortic stenosis based on the extent of cardiac damage
  66. Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses
  67. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement
  68. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
  69. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
  70. Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER Trial)
  71. Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF
  72. Outcomes of Patients With Chronic Lung Disease and Severe Aortic Stenosis Treated With Transcatheter Versus Surgical Aortic Valve Replacement or Standard Therapy
  73. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
  74. Relation Between Six-Minute Walk Test Performance and Outcomes After Transcatheter Aortic Valve Implantation (from the PARTNER Trial)
  75. Paravalvular Leak After Transcatheter Aortic Valve Replacement